Research Evidence / Overview of Studies for Allegra Forte
Evidence for Use in Seasonal Allergic Rhinitis
This section will summarize the core evidence used for regulatory review, primarily derived from short-term Randomized Controlled Trials (RCTs) and systematic reviews, focusing on the outcomes measured for typical seasonal allergy symptoms.
Allegra Forte was studied for the evaluation of symptoms in people with seasonal allergic rhinitis, a condition characterized by fluctuating or episodic manifestations. Research has explored short-term symptom changes through numerous controlled trials, which compared the compound to a placebo (an inactive substance) over defined time intervals, typically two to four weeks. Studies monitored patient-reported outcomes, which included the measurement of the Total Symptom Score (TSS) and individual symptoms such as sneezing, rhinorrhea, and ocular symptoms.
Findings from these short-term trials and subsequent meta-analyses describe patterns observed in the studies. Research highlights changes measured during the study period and contributes to understanding short-term symptom patterns. Research also explored the compound's measurements in studies that included other standard anti-allergic treatments as comparators. Some research examined temporary physiological imbalance linked to symptoms like nasal congestion, and findings were mixed or described as a subject of scientific discussion in systematic reviews.
Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)
The content here will detail the research structure for chronic hives, outlining the types of controlled trials conducted and the specific primary outcomes that were assessed to measure the condition’s physical and functional impact.
The compound was observed in studies examining symptom intensity or variability for chronic idiopathic urticaria (CIU), a condition presenting with cycles of stability and flare-ups. Research designs were primarily short-term RCTs, typically running for four to six weeks. These studies were conducted during periods of increased symptom activity, and outcomes related to systemic or functional imbalance were evaluated. Studies monitored patient-reported outcomes, which included the measurement of the Total Symptom Score (TSS) and individual symptoms such as pruritus (itching) severity and the number of wheals.
Trials reported measurements of pruritus severity and wheal counts when comparing the compound to placebo. Findings describe group patterns related to these outcomes across the studied populations. Research also examined outcomes reflecting daily functioning, such as the degree of interference with sleep and normal daily life activities. Research provides insight into short-term changes in these functional outcomes.
Research in Pediatric and Other Special Populations
This area outlines the evidence landscape for different age groups, summarizing which studies have evaluated outcomes in children, adolescents, and older adults as documented in official regulatory findings.
Evidence for this compound was evaluated in both adult and adolescent populations. Studies exploring its use are also relevant in trials assessing short-term symptom patterns in older adult populations, where findings typically describe group patterns observed in the studies.
Studies in Children and Adolescents
This subheading will present the available data on trial designs and measured outcomes specific to younger patient populations, particularly in the context of allergic rhinitis evaluation.
Studies in children aged 6 to 11 years observed responses over defined time intervals, and research examined patient-reported outcomes. However, the evidence is limited, as data for certain groups remain insufficient and comes from studies with a more modest number of dedicated studies compared to the adult research base.
Long-Term Follow-up and Extended Duration of Evidence
This content will describe the documented duration of the principal clinical trials and what is known regarding data on long-term follow-up and the assessment of sustained outcomes over extended periods.
The majority of the core evidence used for regulatory review comes from studies where follow-up durations were limited, typically lasting only a few weeks. Research exploring short-term symptom changes was conducted, but data are still emerging regarding effects beyond this timeframe.
Therefore, long-term effects are not fully established, and there is limited information for outcomes related to the maintenance of symptom control over extended periods. Existing studies provide limited insight into sustained outcomes or the durability of observed patterns over a multi-season or multi-year period.
Documented Research Gaps and Uncertainties
This final section will synthesize the limitations documented in authoritative scientific reviews, outlining areas where evidence is considered insufficient, such as multi-season data or inconsistent findings for certain measured symptoms.
The research base primarily consists of evidence from systematic reviews of Randomized Controlled Trials. The evidence highlights what is known — and what is still uncertain. Evidence is limited regarding the long-term outcomes and the sustained status of symptoms, as follow-up durations were limited in the primary trials. Data for certain groups remain insufficient, particularly dedicated large-scale trials for certain pediatric subgroups and in specific settings involving individuals with significant comorbidities. Furthermore, subgroup findings are uncertain concerning the consistency of measured changes in certain outcomes, such as the symptom of nasal congestion. Study results reflect the specific conditions under which they were conducted.
